Page 52 - 南京医科大学自然版

第44卷第9期
·1224 · 南 京 医 科 大 学 学 报 2024年9月

A B
0 20 40 60 80 100 1.0
Points
Risk score 0.8
6 7 8 9
Age 0.6
20 40 60 80 100 Observed fraction survival probability
T2 T4 0.4 1⁃year
T 2⁃year
T1 T3 M1 0.2
M 3⁃year
M0 N0 N3
N 0 ldeal line
N1 N2
Sex Male .0 0.2 0.4 0.6 0.8 1.0
Female 1 3 Nomogram predicted survival probability
Stage
4 2 C
Total points 5 year
0 40 80 120 160 200 240 Risk score T N
Linear predictor Age M Sex
-3.5 -2.5 -1.5 -0.5 0.5 1.5 2.5 3.5
Pathological stage
1⁃year survival probability 0.9 0.8 0.7 0.6 0.5 0.4 0.2 Pathological stage+T+M+N+Sex
3⁃year survival probability +Age+Risk score
0.8 0.6 0.4 0.2 Net benefit All positive
5⁃year survival probability 0.1 All negative
0.8 0.6 0.4 0.2
0
00 0.25 0.50 0.75 1.00
Threshold probability
D 5 year E 5 year F 5 year G 5 year
Model Model Model 0.3 New model
0.3 （PMID：30755640） 0.3 （PMID：37370046） 0.3 （PMID：37384293） All positive
All negative
All positive 0.2 All positive 0.2 All positive 0.2 C⁃index（95%CI）：
All negative
All negative
All negative
Net benefit 0.1 C⁃index（95%CI）： Net benefit 0.1 C⁃index（95%CI）： Net benefit 0.1 C⁃index（95%CI）： Net benefit 0.1 0.765（0.747-0.783）
0.2
0.641（0.618-0.663）
0.703（0.683-0.724）
0.640（0.617-0.662）
0 0 0 0
.0 0.2 0.4 0.6 0.8 1.0 .0 0.2 0.4 0.6 0.8 1.0 .0 0.2 0.4 0.6 0.8 1.0 .0 0.2 0.4 0.6 0.8 1.0
Threshold probability Threshold probability Threshold probability Threshold probability
A：Nomogram for predicting the 1，3，5⁃year OS of CRC patients. B：Calibration curve for the prediction of 1，3，5⁃year OS. C：DCA for evaluating
the clinical efficacy of different models. D-G：Comparison of predictive abilities of different models using the C⁃index from the DCA curve.
图5 预后列线图绘制与预后效果评估
Figure 5 Mapping and evaluation of the prognostic nomogram

A Response B Response C Response D NU.7441 *** E
No_response No_response No_response NVP.BEZ235 *** Metfomin ***
DMOG *** ***
CRC_TCGA GSE39582 GSE17536 *** P < 0.001
Bryostatin.1 *** BIBW2992
*** *** AZD6482 ***
100 100 100 AMG.706 *** Sorafenib *** Coefficient
1.0
（%） 75 （%） 75 （%） 75 CCT007093 *** GW.441756 *** 0.5
BX.795 ***
0
Midostaurin ***
Percentage 50 Percentage 50 Percentage 50 GDC0941 *** *** P < 0.001 PF.4708671 *** -0.5
Imatinib ***
-1.0
Dasatinib ***
Coefficient
25
25
25
AZD.0530 ***
JNJ.26854165 *** 1.0
0 0 0 0.5
WO2009093972 *** 0
High risk score
High risk score
Low risk score Low risk score Low risk score Bexarotene *** -0.5
High risk score
PLX4720 ***
-1.0
AG.014699 ***
X17.AAG ***
AP.24534 ***
Pazopanib ***
GSK269962A ***
FTI.277 ***
LFM.A13 ***
A-C：Prediction of the immune efficacy in CRC_TCGA（A），GSE39582（B），and GSE17536（C）cohorts based on PSCRC. D，E：Correlation be⁃
tween IC50 of chemotherapy drugs and PSCRC. Figure 6D showed drugs for which the IC 50 is inversely proportional to the PSCRC risk score，while figure
6E showed drugs whose IC 50 is proportional to the PSCRC risk score. *** P < 0.001.
图6 PSCRC的疗效预测
Figure 6 Prediction of the efficacy based on PSCRC